Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 608-614

  Källén, Bengt ^a   Reis, Margareta ^b  

^a UNIVERSITY OF LUND   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

CNS active drugs; drug combinations; neonatal morbidity; selective serotonin reuptake inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CODEINE; DEXTROPROPOXYPHENE; DIAZEPAM; DIXYRAZINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LAMOTRIGINE; LITHIUM; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE DERIVATIVE; OXAZEPAM; PARACETAMOL; PROCHLORPERAZINE; PROPIOMAZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; UNINDEXED DRUG; VALPROIC ACID; ZOLPIDEM; ZOPICLONE;

ADULT; APGAR SCORE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CONVULSION; DELIVERY; DISEASE REGISTRY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; HYPOGLYCEMIA; INFANT; MAJOR CLINICAL STUDY; MATERNAL CARE; NEWBORN; NEWBORN DISEASE; NEWBORN MORBIDITY; PATHOPHYSIOLOGY; POLYPHARMACY; PREGNANT WOMAN; PREMATURE LABOR; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADULT; APGAR SCORE; CENTRAL NERVOUS SYSTEM AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MIDDLE AGED; POLYPHARMACY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; SEROTONIN UPTAKE INHIBITORS; SWEDEN; YOUNG ADULT;

EID: 84865860691     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182668568     Document Type: Article

References (24)

1. Sanz E, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
2. Chambers CD, Chambers BA, Johnson KA, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
3. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
4. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA. 2005;293:2372-2383.
5. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106:1289-1296.
6. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898-906.
7. Oberlander TF, Warburton W, Misri S, et al. Effect of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338-343.
8. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16:1086-1094.
9. Ferreira E, Carceller AM, Agogué C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrcs. 2007;19:52-59.
10. Yonkers KA, Wisner K, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403-413.
11. Källén B. Drugs During Pregnancy. New York, NY: Nova Biomedical Books; 2009.
12. Levy M, Spino M. Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy. 1993;13:202-211.
13. Agthe A, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123:e849Ye856.
14. Ebbesen F, Joergensen A, Hoseth E, et al. Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. Arch Dis Child Fetal Neonatal Ed. 2000;83:F124YF129.
15. Gillberg G. "Floppy infant syndrome" and maternal diazepam. Lancet. 1977;2:244.
16. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8:461-475.
17. Norstedt Wikner B, Stiller C-O, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy. Neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1203-1210.
18. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36:518-544.
19. Källén B, Nilsson E, Otterblad Olausson P. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol. 2011;67:834-845.
20. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug RegisterVopportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-735.
21. National Board of Health and Welfare, Centre for Epidemiology. The Swedish Medical Birth RegistryVa summary of content and quality. 2003. Available at: http://www.sos.se/publikationer2003/2003-112-3. Accessed on September 1, 2011.
22. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279-288.
23. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;10:1723-1733.
24. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.